Drugs in R & D

, Volume 9, Issue 4, pp 261–269

Aflibercept

AVE 0005, AVE 005, AVE0005, VEGF Trap — Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye
Adis R&D Profile

References

  1. 1.
    Bayer HealthCare, Regeneron Pharmaceuticals Inc. Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases. Media Release: 18 Oct 2006. Available from URL: http://www.bayer.com Google Scholar
  2. 2.
    Regeneron Pharmaceuticals Inc. Sanofi-Aventis and Regeneron Pharmaceuticals Expand Their VEGF Trap Oncology Collaboration to Japan. Media Release: 22 Dec 2005. Available from URL: http://www.sanofi-aventis.com Google Scholar
  3. 3.
    sanofi-aventis. Sanofi-aventis and Regeneron Pharmaceuticals Reaffirm Development Commitment. Media Release: 10 Jan 2005. Available from URL: http://www.sanofi-aventis.com Google Scholar
  4. 4.
    Aventis, Regeneron Pharmaceuticals Inc. Aventis and Regeneron Enter Global Partnership to Develop and Commercialize the VEGF Trap. Media Release: 8 Sep 2003. Available from URL: http://www.aventis.com
  5. 5.
    Massarelli E, Miller VA, Leighl NB, et al. Phase II study of the efficacy and safety of intravenous AVE0005 (VEGF Trap) given every 2 weeks in patients with platinum- and erlotinib-resistant adenocarcinoma of the lung. Journal of Clinical Oncology 25 (Suppl.): 416 (plus poster) abstr. 7627, No. 18, Part 1, 20 Jun 2007Google Scholar
  6. 6.
    Regeneron Pharmaceuticals Inc. Regeneron Reports Fourth Quarter and Full Year 2005 Financial and Operating Results. Media Release: 24 Feb 2006. Available from URL: http://www.regeneron.com Google Scholar
  7. 7.
    Regeneron Pharmaceuticals Inc. Regeneron Reports Positive Preliminary Results from Phase 1 Study of the VEGF Trap in Patients with Advanced Solid Tumors. Media Release: 6 Jun 2004. Available from URL: http://www.regn.comGoogle Scholar
  8. 8.
    Regeneron Pharmaceuticals Inc. Regeneron Reports Second Quarter Financial and Operating Results; BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007; Two Antibody Candidates from VelocImmune(R) Program to Enter Clinical Trials Each Year Beginning in 2007. Media Release: 3 Aug 2006. Available from URL: http://www.regeneron.com
  9. 9.
    Regeneron Pharmaceuticals Inc. Regeneron’s VEGF Trap Demonstrates Positive Preliminary Results from Single-Agent Phase 1 Trial in Patients with Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005. Media Release: 16 May 2005. Available from URL: http://www.regeneron.com Google Scholar
  10. 10.
    Regeneron Pharmaceuticals Inc. Regeneron Receives $20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD. Media Release: 14 Aug 2007. Available from URL: http://www.regeneron.com Google Scholar
  11. 11.
    Regeneron Pharmaceuticals Inc, Bayer HealthCare. Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD). Media Release: 3 Aug 2007. Available from URL: http://www.regeneron.com Google Scholar
  12. 12.
    Bayer HealthCare AG. Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration. Media Release: 8 May 2008. Available from URL: http://www.bayerscheringpharma.de Google Scholar
  13. 13.
    Bayer HealthCare AG, Regeneron Pharmaceuticals Inc. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration. Media Release: 8 May 2008. Available from URL: http://www.bayerhealthcare.com Google Scholar
  14. 14.
    Regeneron Pharmaceuticals Inc, Bayer HealthCare AG. Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration. Media Release: 29 Apr 2008. Available from URL: http://www.regeneron.com Google Scholar
  15. 15.
    Regeneron Pharmaceuticals Inc. Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration. Media Release: 1 Oct 2007. Available from URL: http://www.regeneron.com Google Scholar
  16. 16.
    Regeneron Pharmaceuticals Inc. Regeneron Reports Positive Phase 1 Data for the VEGF Trap in Age-Related Macular Degeneration; Preliminary Results Show Improvements in Vision and Retinal Swelling; VEGF Trap Was Well Tolerated at All Dose Levels. Media Release: 1 May 2006. Available from URL: http://www.regeneron.com Google Scholar
  17. 17.
    Regeneron Pharmaceuticals Inc. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting. Media Release: 10 May 2007. Available from URL: http://www.regeneron.com Google Scholar
  18. 18.
    Regeneron Pharmaceuticals Inc. Regeneron Reports Fourth Quarter and Full Year 2004 Financial and Operating Results. Media Release: 22 Feb 2005. Available from URL: http://www.regeneron.com Google Scholar
  19. 19.
    Regeneron Pharmaceuticals Inc. Clinical and Pre-Clinical Studies of the VEGF Trap Show Potential for the Treatment of Neovascular Eye Diseases. Media Release: 3 May 2005. Available from URL: http://www.regeneron.com Google Scholar
  20. 20.
    Dupont J, Camastra D, Gordon MS, et al. Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. 39th Annual Meeting of the American Society of Clinical Oncology: 194, 31 May 2003Google Scholar
  21. 21.
    Dupont J, Schwartz L, Koutcher J, et al. A phase I and pharmacokinetic clinical trial of subcutaneous VEGF Trap in advanced solid tumor patients. EJC Supplements 2: 43 (plus poster) abstr. 132, 29 Sep 2004Google Scholar
  22. 22.
    Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proceedings of the National Academy of Sciences of the United States of America 100: 7785–7790, 24 Jun 2003PubMedCrossRefGoogle Scholar
  23. 23.
    Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clinical Cancer Research 9: 5721–5728, No. 15, 15 Nov 2003PubMedGoogle Scholar
  24. 24.
    Johns Hopkins’ Wilmer Eye Institute. Injection Prevents Blinding Blood Vessel Growth in Mice. Media Release: 17 Jun 2003. Available from URL: http://www.hopkinsmedicine.org Google Scholar
  25. 25.
    Regeneron Pharmaceuticals Inc. Regeneron’s VEGF Trap Demonstrates Positive Preliminary Results in Patients with Age-Related Macular Degeneration; Phase 1 Preliminary Results to Be Presented at the Angiogenesis 2006 Meeting Sponsored by Bascom Palmer Eye Institute. Media Release: 2 Feb 2006. Available from URL: http://www.regeneron.com Google Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations